# A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)

> **NCT05192486** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** GNC-038

## Key facts

- **NCT ID:** NCT05192486
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-10
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05192486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05192486, "A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05192486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*